## Medical Control Guideline: DRUG REFERENCE – EPINEPHRINE

Ref. No. 1317.17

#### Classification

Sympathomimetic

# **LA County Prehospital Indications**

Anaphylaxis

Cardiac Arrest – Non-Traumatic: cardiac arrest resuscitation, hypotension after return of spontaneous circulation (ROSC) not responsive to IV fluid resuscitation

Cardiac Dysrhythmia: symptomatic bradycardia not responsive to atropine and transcutaneous pacing for adults; and for symptomatic bradycardia unresponsive to oxygenation and ventilation for pediatric patients

Respiratory Distress / Bronchospasm: asthma, reactive bronchospasm (unlikely to benefit in COPD)

Airway Obstruction: stridor or visible airway swelling, croup/tracheitis in pediatrics

Shock / Hypotension: non-traumatic hypotension not responsive to IV fluid resuscitation

# Other Common Indications (Not authorized for EMS administration in LA County)

None

#### **Adult Dose**

Anaphylaxis

**0.5mg (1mg/mL) IM** in the lateral thigh, may repeat every 10 min x2 prn, maximum total 3 doses Cardiac Arrest

1mg (0.1mg/mL) 10mL IV/IO may repeat every 5 min x2, maximum total dose 3mg

Non-traumatic shock (including from symptomatic bradycardia or after ROSC)

**Push-dose epinephrine** – mix 9mL normal saline with 1mL epinephrine 0.1mg/mL (IV formulation) in a 10mL syringe. Administer push-dose epinephrine 1mL IV/IO every 1-5 min as needed to maintain SBP >90mmHg

Respiratory Distress/Bronchospasm

0.5mg (1mg/mL) IM in the lateral thigh

Airway Obstruction - Stridor

Epinephrine (1mg/mL solution) administer 5mg (5mL) via neb, repeat x1 in 10 min prn

Airway Obstruction - Airway swelling

**Epinephrine (1mg/mL) administer 0.5mg (0.5mL) IM**, repeat every 10 min prn x2, maximum total 3 doses

#### **Pediatric Dose**

Anaphylaxis

**0.01mg/kg (1mg/mL) IM**, dose per *MCG 1309*, in the lateral thigh, may repeat every 10 min x2 prn for persistent symptoms, maximum total 3 doses

Cardiac Arrest

**0.01mg/kg (0.1mg/mL) IV/IO**, dose per *MCG 1309*, may repeat every 5 min, maximum single dose 1mg, and maximum 3 total doses

Cardiac Dysrhythmia - Symptomatic bradycardia

0.01mg/kg (0.1mg/mL) slow IV/IO push, dose per MCG 1309

Shock / Hypotension (including hypotension after ROSC)

**Push-dose epinephrine** – mix 9mL normal saline with 1mL epinephrine (0.1mg/mL) IV formulation in a 10mL syringe. Administer push-dose epinephrine (0.01mg/mL), dose per *MCG* 1309 every 1-5 min as needed to maintain SBP >70mmHg

Respiratory Distress/Bronchospasm

Epinephrine (1mg/mL) 0.01mg/kg IM in the lateral thigh, dose per MCG 1309

Airway obstruction - Stridor from croup/tracheitis

<1 year old: **Epinephrine (1mg/mL) 2.5mL via neb**, dose per *MCG 1309* 

≥ 1 year of age: Epinephrine (1mg/mL) 5mL via neb, dose per MCG 1309

Repeat x1 in 10 min prn, maximum 2 total doses prior to Base contact

Airway obstruction - Airway swelling

REVISED: 07-01-24 PAGE 1 OF 2

# Medical Control Guideline: DRUG REFERENCE – EPINEPHRINE

Ref. No. 1317.17

**Epinephrine (1mg/mL) 0.01mg/kg IM** dose per *MCG 1309*, repeat every 10 min prn x2, maximum 3 total doses prior to Base contact

#### **Mechanism of Action**

A naturally occurring catecholamine. Acts directly on alpha and beta adrenergic receptors. It is the most potent activator of alpha receptors vasoconstricting the aorta and peripheral vasculature. Beta 1 stimulation increases inotropy, chronotropy, and AV conduction. Beta 2 stimulation causes bronchial smooth muscle relaxation and vasodilation to internal organs and skeletal muscles.

#### **Pharmacokinetics**

Onset is < 2 min IV, 1-3 min IM; duration is 5-10 min IV, 20-30 min IM

#### **Contraindications**

None

#### Interactions

Can be partially deactivated by highly alkaline solutions, such as sodium bicarbonate.

## **Adverse Effects**

Anxiety
CVA or MI (rare, IV only)
Hypertension
Palpitations
Tachydysrhythmias
Tremors

## **Prehospital Considerations**

 Inadvertent IV injection of usual IM formulation and dose constitutes a 10-fold overdose that can result in sudden severe hypertension and possible cerebral hemorrhage.

REVISED: 07-01-24 PAGE 2 OF 2